ArticleChinese medicine2025
Hypericum perforatum L. extract alleviates metabolic-associated fatty liver disease through inflammation, lipid metabolism and ferroptosis modulation: a multi-omics perspective.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis: A Novel Mechanism and Therapeutic Target of Traditional Chinese Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypericum perforatum L. (Guan Ye Jin Si Tao, GYJST), commonly known as St. John's wort, is a widely distributed medicinal plant across Europe and Asia. Preclinical studies have identified its therapeutic potential in both neurological and metabolic disorders. However, its impact on metabolic-associated fatty liver disease (MAFLD) remains unclear. This study comprehensively investigated the therapeutic effects of GYJST on MAFLD through both in vivo and in vitro experiments. Utilizing a multi-omics approach, the research elucidated the regulatory mechanisms of GYJST on ferroptosis, focusing on oxidative stress, lipid metabolism, and inflammatory response modulation. The findings provide valuable insights into the potential therapeutic applications of GYJST in managing MAFLD. MATERIALS AND
methodsLiver assessments were systematically conducted to evaluate the therapeutic effects of GYJST on HFD-induced mice and PA-induced AML12 cells. Comprehensive histological analyses, including H&E, Masson, Sirius Red, Oil Red O, and F4/80 staining, were performed to assess the impact of GYJST on liver pathology. To elucidate the underlying mechanisms of GYJST, a multi-omics approach was employed, integrating network pharmacology, transcriptomics, proteomics, and metabolomics. Additionally, RT-qPCR, western blotting, and immunofluorescence techniques were utilized to validate the effects of GYJST.
resultsGYJST effectively protects against liver injury by mitigating inflammation, oxidative stress, and lipid metabolism dysregulation. A total of 90 major compounds in GYJST were tentatively identified. Network pharmacology analysis revealed its multi-target, multi-pathway mechanisms of action. Integrative transcriptomic, metabolomic, and proteomic analyses consistently highlighted pathways associated with inflammatory responses, oxidative stress, and lipid metabolism. Mechanistically, GYJST suppresses systemic inflammation via the NF-κB/COX-2 signaling axis and alleviates oxidative stress and lipid accumulation through the Nrf2/PPARα/g pathway. Additionally, GYJST plays a crucial role in inhibiting ferroptosis, partly through Nrf2-mediated mechanisms.
conclusionGYJST exerts multi-target therapeutic effects against MAFLD by concurrently regulating ferroptosis, oxidative stress, lipid metabolism, and inflammation through interconnected mechanisms. These findings establish GYJST as a promising multi-target therapeutic candidate for MAFLD treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.